CONTEXT AND OBJECTIVE: Bordetella bronchiseptica (BB) is a Gram-negative coccobacillus responsible for respiratory diseases in dogs, cats and rabbits. Reports on its development in humans are rare. However, in immunosuppressed patients, especially in those with the immunodeficiency virus (HIV), BB can cause severe pulmonary infections. We report on two cases of pneumonia caused by BB in HIV-positive male patients in a university hospital. CASE REPORT: The first case comprised a 43-year-old patient who was admitted presenting chronic leg pain and coughing, with suspected pneumonia. BB was isolated from sputum culture and was successfully treated with trimethoprim/sulfamethoxazole in association with levofloxacin. The second case comprised a 49-year-old patient who was admitted presenting fever, nausea, sweating and a dry cough, also with suspected pneumonia. BB was isolated from sputum culture, tracheal secretions and bronchoalveolar lavage. The disease was treated with ciprofloxacin but the patient died. CONCLUSION: BB should be included in the etiology of pneumonia in immunodeficient HIV patients. As far as we know, these two were the first cases of pneumonia due to BB to occur in this university hospital. 
INTRODUCTION
Bordetella bronchiseptica (BB) is a strictly aerobic Gram-negative coccobacillus that causes diseases in the respiratory tract of animals, such as infectious tracheobronchitis or "canine cough" and pneumonitis in dogs, pneumonia in cats, coryza, pneumonia and otitis media in rabbits and bronchopneumonia in pigs. [1] [2] [3] [4] [5] Infections caused by BB are rare in humans but this bacterium can be isolated as a commensal agent in the human respiratory tract.
1,2,4-6 BB occurs independently from contact with colonized animals, and can persist in the environment for long periods of time. 7, 8 In general, humans acquire BB through contact with domestic animals but this can also occur through cross-contamination with hospital patients. 1, 2 In human beings, BB preferentially attacks the respiratory tract and can cause severe pulmonary infections, such as infectious bronchitis, pneumonia and bacteremia. It generally occurs in patients with weak immune systems, such as AIDS patients. [6] [7] [8] [9] Two cases of pneumonia caused by BB in HIV-positive patients at a university hospital are reported below.
CASE REPORTS

Report 1
The patient was a 43-year-old HIV-positive man who had been In May 2014, the patient was admitted again for treatment of disseminated AIDS-related disease, presenting a viral load of 589 copies/ml (reference value, RV: 493-1666 copies/ml) and CD8 212 cell/ml (RV: 224-1112 cell/ml). it was resistant to cefuroxime, cefuroxime axetil, ceftriaxone, nitrofurantoin and trimethoprim/sulfamethoxazole. Thus, the antimicrobial therapy was changed to levofloxacin. The blood culture was negative.
The patient was released at the end of May 2014, with a recommendation to use HIV antiretroviral medication and the antimicrobial agent for an additional seven days.
Report 2
The patient was a 49-year-old male who had been diagnosed positive for HIV, AIDS and HCV in 2012, with no treatment. (RV: 493-1666 cell/ml) and CD8 180 cell/ml (RV: 224-1112 cell/ml).
He presented symptoms of peritoneal irritation. He had also been suffering from dyspnea and a dry cough for the last five days.
He was suspected of having pneumonia, as shown on lung radiography (Figure 2) . Therefore, empirical treatment for pneumonia was started. At the end of May he was taken to the intensive care unit (ICU) because of complications.
At the beginning of June 2014, the patient presented respiratory insufficiency. Thoracic computed tomography (CT) was performed, focusing especially on the right side (Figure 3) . and treatment with levofloxacin, trimethoprim/sulfamethoxazole and azithromycin was successfully used. The patient had been in contact with a domestic dog. 9 Wernli et al. described eight cases of BB that caused infection or colonization in human beings over a 15-year period. 16 Those researchers showed that seven of their patients had underlying diseases and that only three had been in contact with domestic animals. The patients' symptoms ranged from no symptoms to severe pneumonia. It was not possible to establish a homogeneous pattern regarding clinical disease among the symptomatic patients.
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A study by García-de-la-Fuente et al. in 2015 showed that most of the patients from whom BB was isolated presented a compromised immune system as well as an underlying disease, and 82% presented respiratory symptoms. 17 Respiratory tract diseases are the major cause of morbidity and mortality among AIDS patients. The etiology of these respiratory infections varies according to factors such as CD4 levels, location of home, socioeconomic conditions and use of chemoprophylaxis. The CD4 count is the main risk predictor for progression to AIDS and death among HIV-positive patients. 18 Although B. bronchiseptica is only rarely isolated in humans, it should be considered to be potentially pathogenic when found in samples from the respiratory tract in patients with a compromised immune system. [4] [5] [6] 16 Sputum culturing and investigation of exposure to animals are recommended. 9, 16 It became known that the patient in Report 2 had been in contact with 25 domestic dogs. These animals were the potential source of the acquired infection.
1,2
Empirical antibiotic therapy using trimethoprim/sulfamethoxazole can be justified, given that this drug is the first choice for treating pulmonary pneumocystosis. This is caused by the unicellular fungus Pneumocystis jiroveci, a saprophyte of the respiratory tract that causes pneumonia in many HIV-positive patients. Its occurrence decreases substantially through antiretroviral therapy. 18, 19 Given that the antimicrobial treatment for infections caused by BB has not been clearly established, ascertaining the sensitivity profile of the antimicrobials is fundamental. 20 García-de-la-Fuente et al. studied 36 respiratory tracts from which BB was isolated and found that the minimum inhibitory concentration (MIC) of antimicrobial agents was smaller for tigecycline, colistin, tetracycline, minocycline, doxycycline and meropenem;
and it was larger for beta-lactams, macrolides and trimethoprim/ sulfamethoxazole. 17 According to other studies, this microorganism generally presents strong resistance to macrolides and clindamycin. Thus, treatment can be done using trimethoprim/ sulfamethoxazole, fluoroquinolones and penicillins. 11, 16 Other studies have reported 100% sensitivity in vitro to aminoglycosides, penicillins and cephalosporins with anti-Pseudomonas activity, and to carbapenems, quinolones and tetracyclines. 6 The for the more resistant isolates.
21
B. bronchiseptica has only rarely been isolated from clinical human specimens, in spite of the considerable exposure to this microorganism through colonized animals. 7 Antimicrobial treatment should be started as soon as possible, especially in immunocompromised patients.
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CONCLUSION
In spite of the fact that BB is associated with colonization in the respiratory tract and bronchopulmonary disease, it is difficult to clearly establish the pathogenic effect of this microorganism in human beings; its isolation presents challenging results. However, BB should be considered to be a possible agent for pneumonia since it has virulence factors, such as production of toxins. Isolation of BB from biological materials makes it possible to know its resistance profile, which can improve the prognosis considerably. As far as we know, up to the present time, the two cases reported above were the first cases in this university hospital.
